Earnings ·
Bolt Biotherapeutics reported financial results for the second quarter ended June 30, 2026
BOLTBolt Biotherapeutics, Inc.
Bolt Biotherapeutics reported financial results for the second quarter ended June 30, 2026. The company generated collaboration revenue of $5,000 and incurred a net loss of $7.7 million. Operating expenses decreased to $8.4 million from $9.2 million in the prior year period due to restructuring and lower research activities. Cash and marketable securities totaled $18.1 million as of June 30, 2026, which management anticipates will fund operations into the first quarter of 2027. Clinically, the Phase 1/2 study for BDC-4182 in gastric and gastroesophageal cancer is ongoing with patients treated in Cohort 4 at 4.0 mg/kg; initial clinical data is expected with third-quarter results. Bolt Biotherapeutics operates as a clinical-stage biopharmaceutical company developing novel immunotherapies, specifically immune-stimulating antibody conjugates, for the treatment of cancer.